ArticleFrontiers in medicine2025
The prognostic value of Clinical Frailty Scale in COVID-19 pneumonia across different pandemic phases: a comparison between the first and the fourth wave.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interplay between frailty and cardiometabolic disorders: from pathophysiology to clinical implications.Cardiovascular diabetology · 2025Pooled it
- Atrial Fibrillation and Documented Heart Failure in Patients Hospitalized with COVID-19: A Secondary Analysis of a Single-Centre Cohort from Western Romania.Journal of clinical medicine · 2026Article
- Clinical Spectrum and Exploratory Mortality Markers in Hospitalized Patients with Different Clinical Presentations of West Nile Virus Infection: A Multicenter Cohort from Southern Italy.Medicina (Kaunas, Lithuania) · 2026Observational
- Evolutionary Predictors of Post-COVID Syndrome.Journal of clinical medicine · 2026Article
- Six Years of COVID-19: Lessons from Epidemiology, Vaccination Campaigns, Clinical Risk Stratification, and Thromboembolic Surveillance.Vaccines · 2026Review
- Article
- Lung Ultrasound Abnormalities and LUS Score After COVID-19 Pneumonia: Determinants and Associations with Dyspnoea in a Prospective Cohort.Journal of clinical medicine · 2026Article
- OPG and TNFR1 as Potential Biomarkers of Inflammation in Older Adults with Acute COVID-19 and Indicators of Frailty in Post-COVID-19: A Pilot Study.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The COVID-19 pandemic has placed unprecedented strain on health-care systems. Frailty is being used in clinical decision making for patients with COVID-19, yet the prevalence and effect of frailty in people with COVID-19 may be influenced by the local characteristics of each pandemic wave. We aimed to establish the prevalence of frailty in older patients with COVID-19 who were admitted to hospital and investigate its association with mortality comparing non-vaccinated patients of the first wave versus vaccinated patients in the fourth wave. Materials and methods: This was an observational study conducted at one single hospital center in Italy. All older adults (≥70 years) admitted with confirmed COVID-19 (positive molecular testing) were included. Data of 658 patients (493 non-vaccinated COVID-19 patients admitted during the first wave and 165 patients vaccinated against COVID-19 during the fourth wave), were collected from clinical records including symptom type, extension of lung abnormalities on chest computed tomography (CT), laboratory parameters. Frailty was assessed by Clinical Frailty Scale (CFS) and patients were grouped according to their score (≤4: fit or pre-frail; 5-6 = initial signs of frailty but with some degree of independence; >7 = severe or very severe frailty). The primary outcome was in-hospital mortality. Results: In comparison with vaccinated patients from the fourth wave, unvaccinated patients from the first wave had reduced prevalence of heart disease (35% vs. 56%), renal failure (9% vs. 15%), but higher prevalence of fever at time of diagnosis (84% vs. 59%), malignancy (16% vs. 6%), higher computed tomography (CT) severity visual score, higher CRP (C-reactive protein) serum levels (median value 105 mg/L vs. 75 mg/L), but lower burden of frailty. In a stepwise multivariable logistic regression model, unvaccinated patients from the first wave had a higher risk of death regardless of CFS [Odds Ratio (OR) 2.241, 95% confidence interval (CI) 1.492-3.336, Conclusion: Our study suggests that in non-vaccinated older patients from the first pandemic wave CFS was unable to stratify the risk of death.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.